Kavita U - Search Results

1

Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection.

Leng J, Stout-Delgado HW, Kavita U, Jacobs A, Tang J, Du W, Tussey L, Goldstein DR. Leng J, et al. Among authors: kavita u. Vaccine. 2011 Oct 19;29(45):8147-55. doi: 10.1016/j.vaccine.2011.08.027. Epub 2011 Aug 18. Vaccine. 2011. PMID: 21854824 Free PMC article.

2

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. Turley CB, et al. Among authors: kavita u. Vaccine. 2011 Jul 18;29(32):5145-52. doi: 10.1016/j.vaccine.2011.05.041. Epub 2011 May 30. Vaccine. 2011. PMID: 21624416 Clinical Trial.

3

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).

Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A. Taylor DN, et al. Among authors: kavita u. Vaccine. 2011 Jul 12;29(31):4897-902. doi: 10.1016/j.vaccine.2011.05.001. Epub 2011 May 17. Vaccine. 2011. PMID: 21596084

4

Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin.

Song L, Zhang Y, Yun NE, Poussard AL, Smith JN, Smith JK, Borisevich V, Linde JJ, Zacks MA, Li H, Kavita U, Reiserova L, Liu X, Dumuren K, Balasubramanian B, Weaver B, Parent J, Umlauf S, Liu G, Huleatt J, Tussey L, Paessler S. Song L, et al. Among authors: kavita u. Vaccine. 2009 Sep 25;27(42):5875-84. doi: 10.1016/j.vaccine.2009.07.060. Epub 2009 Aug 3. Vaccine. 2009. PMID: 19654064 Free PMC article.

5

Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults.

Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, Liu G, Kavita U, Song L, Dark I, Shaw A. Treanor JJ, et al. Among authors: kavita u. Vaccine. 2010 Dec 6;28(52):8268-74. doi: 10.1016/j.vaccine.2010.10.009. Epub 2010 Oct 20. Vaccine. 2010. PMID: 20969925 Clinical Trial.

6

Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response.

Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, Hofstaetter T, Shaw A. Taylor DN, et al. Among authors: kavita u. Vaccine. 2012 Aug 24;30(39):5761-9. doi: 10.1016/j.vaccine.2012.06.086. Epub 2012 Jul 11. Vaccine. 2012. PMID: 22796139 Clinical Trial.

7

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, Jacobs A, Liu G, Huang Y, Desai P, Maksymiuk G, Takahashi V, Umlauf S, Reiserova L, Bell R, Li H, Zhang Y, McDonald WF, Powell TJ, Tussey L. Song L, et al. Among authors: kavita u. PLoS One. 2008 May 21;3(5):e2257. doi: 10.1371/journal.pone.0002257. PLoS One. 2008. PMID: 18493310 Free PMC article.

8

Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin.

Talbot HK, Rock MT, Johnson C, Tussey L, Kavita U, Shanker A, Shaw AR, Taylor DN. Talbot HK, et al. Among authors: kavita u. PLoS One. 2010 Dec 28;5(12):e14442. doi: 10.1371/journal.pone.0014442. PLoS One. 2010. PMID: 21203437 Free PMC article. Clinical Trial.

9

A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.

Kavita U, Duo J, Crawford SM, Liu R, Valcin J, Gleason C, Dong H, Gadkari S, Dodge RW, Pillutla RC, DeSilva BS. Kavita U, et al. J Immunol Methods. 2017 Sep;448:91-104. doi: 10.1016/j.jim.2017.06.002. Epub 2017 Jun 16. J Immunol Methods. 2017. PMID: 28625864

10

Development of a Chemiluminescent ELISA Method for the Detection of Total Anti-Adeno Associated Virus Serotype 9 (AAV9) Antibodies.

Kavita U, Dai Y, Salvador L, Miller W, Adam LP, Levesque PC, Zhang YJ, Ji QC, Pillutla RC. Kavita U, et al. Hum Gene Ther Methods. 2018 Dec;29(6):237-250. doi: 10.1089/hgtb.2018.131. Epub 2018 Nov 22. Hum Gene Ther Methods. 2018. PMID: 30351228

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters